NXL: Nexalin Technology Inc. Stocks News on May 9, 2025

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

NXL

GlobeNewswire

3 days ago

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

NXL

MT Newswires

4 days ago

Nexalin Shares Fall After Pricing of $5 Million Public Offering

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

NXL

GlobeNewswire

4 days ago

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

NXL

GlobeNewswire

8 days ago

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

NXL

GlobeNewswire

15 days ago

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

NXL

GlobeNewswire

16 days ago

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

NXL

GlobeNewswire

18 days ago

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Nexalin secures patent on brain stimulation method for substance use disorders

NXL

Medical Device Network

24 days ago

Nexalin secures patent on brain stimulation method for substance use disorders

NXL

MT Newswires

25 days ago

Nexalin Secures Patent for Intracranial Stimulation Technology

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

NXL

GlobeNewswire

25 days ago

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

NXL

GlobeNewswire

a month ago

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3

NXL

GlobeNewswire

a month ago

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3

NXL

ACCESS Newswire

2 months ago

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

NXL

GlobeNewswire

2 months ago

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

UCSD begins trial with Nexalin’s Halo Clarity device for mTBI and PTSD

NXL

Medical Device Network

2 months ago

UCSD begins trial with Nexalin’s Halo Clarity device for mTBI and PTSD

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval

NXL

GlobeNewswire

2 months ago

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

NXL

GlobeNewswire

2 months ago

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

NXL

MT Newswires

3 months ago

Nexalin Technology Says Halo Clarity Headset Clinical Testing Gets UCSD Institutional Review Board Approval

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

NXL

GlobeNewswire

3 months ago

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

NXL

GlobeNewswire

3 months ago

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

NXL

GlobeNewswire

3 months ago

Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

NXL

Argus Research

3 months ago

Daily – Vickers Top Buyers & Sellers for 01/27/2025

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23

NXL

GlobeNewswire

4 months ago

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025

NXL

GlobeNewswire

4 months ago

Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

NXL

GlobeNewswire

5 months ago

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

NXL

MT Newswires

5 months ago

Nexalin Files for Potential Stock Sale by Maxim Partners

New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

NXL

GlobeNewswire

5 months ago

New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Nexalin Technology CEO Provides Letter to Shareholders

NXL

GlobeNewswire

6 months ago

Nexalin Technology CEO Provides Letter to Shareholders

Is Nexalin Technology (NASDAQ:NXL) In A Good Position To Invest In Growth?

NXL

Simply Wall St.

6 months ago

Is Nexalin Technology (NASDAQ:NXL) In A Good Position To Invest In Growth?

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th

NXL

GlobeNewswire

6 months ago

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th

NXL

MT Newswires

6 months ago

Nexalin Technology Regains Nasdaq Compliance Over Minimum Bid Price; Shares Rise

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

NXL

GlobeNewswire

6 months ago

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NXL

ACCESSWIRE

6 months ago

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

NXL

GlobeNewswire

6 months ago

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

EXCLUSIVE: Nexalin Technology Says New Data Confirms Investigational Non-Invasive Neurostimulation Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients (UPDATED)

NXL

Benzinga

6 months ago

EXCLUSIVE: Nexalin Technology Says New Data Confirms Investigational Non-Invasive Neurostimulation Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients (UPDATED)

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NXL

ACCESSWIRE

6 months ago

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin trials Halo neurostimulation device in traumatic brain injury

NXL

Clinical Trials Arena

7 months ago

Nexalin trials Halo neurostimulation device in traumatic brain injury

NXL

MT Newswires

7 months ago

Sector Update: Health Care Stocks Softer Late Afternoon

NXL

MT Newswires

7 months ago

Nexalin Technology Shares Rise After Clinical Trial Set for Halo Headset in Traumatic Brain Injuries

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

NXL

GlobeNewswire

7 months ago

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

Mixed results for Nexalin’s transcranial alternating current stimulation trial

NXL

Medical Device Network

7 months ago

Mixed results for Nexalin’s transcranial alternating current stimulation trial

NXL

Clinical Trials Arena

7 months ago

Mixed results for Nexalin’s transcranial alternating current stimulation trial

New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients

NXL

GlobeNewswire

7 months ago

New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients

EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study

NXL

Benzinga

7 months ago

EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

NXL

GlobeNewswire

7 months ago

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

NXL

GlobeNewswire

8 months ago

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

Nexalin Technology Second Quarter 2024 Earnings: US$0.17 loss per share (vs US$0.11 loss in 2Q 2023)

NXL

Simply Wall St.

9 months ago

Nexalin Technology Second Quarter 2024 Earnings: US$0.17 loss per share (vs US$0.11 loss in 2Q 2023)

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NXL

ACCESSWIRE

9 months ago

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

NXL

GlobeNewswire

10 months ago

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

NXL

MT Newswires

10 months ago

Nexalin Technology Says It Regains Nasdaq Compliance Following Stock Offering; Shares Fall

NXL

MT Newswires

10 months ago

Nexalin Technology Completes $5.3 Million Share Offering

Nexalin Technology Announces Closing of $5.2 Million Public Offering

NXL

GlobeNewswire

10 months ago

Nexalin Technology Announces Closing of $5.2 Million Public Offering

NXL

MT Newswires

10 months ago

Top Midday Decliners

NXL

MT Newswires

10 months ago

Top Premarket Decliners

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

NXL

GlobeNewswire

10 months ago

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

Nexalin’s deep brain stimulation add-on therapy alleviates depression

NXL

Medical Device Network

10 months ago

Nexalin’s deep brain stimulation add-on therapy alleviates depression

Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal

NXL

GlobeNewswire

10 months ago

Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal

Nexalin secures US patent for Alzheimer’s deep-brain stimulation device

NXL

Medical Device Network

a year ago

Nexalin secures US patent for Alzheimer’s deep-brain stimulation device

Nano-Cap Nexalin Technology Secures US Patent For Stimulation Device For Alzheimer's And Dementia Treatment

NXL

Benzinga

a year ago

Nano-Cap Nexalin Technology Secures US Patent For Stimulation Device For Alzheimer's And Dementia Treatment

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

NXL

GlobeNewswire

a year ago

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NXL

ACCESSWIRE

a year ago

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

NXL

GlobeNewswire

a year ago

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies

NXL

ACCESSWIRE

a year ago

MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies

Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

NXL

GlobeNewswire

a year ago

Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

NXL

GlobeNewswire

a year ago

FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

NXL

GlobeNewswire

a year ago

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts

Nexalin Technology First Quarter 2024 Earnings: US$0.14 loss per share (vs US$0.10 loss in 1Q 2023)

NXL

Simply Wall St.

a year ago

Nexalin Technology First Quarter 2024 Earnings: US$0.14 loss per share (vs US$0.10 loss in 1Q 2023)

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23

NXL

GlobeNewswire

a year ago

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23

NXL

MT Newswires

a year ago

Nexalin Technology Regains Compliance With Nasdaq Listing Requirement

NXL

GlobeNewswire

a year ago

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

NXL

GlobeNewswire

a year ago

Nexalin Technology CEO Provides Letter to Shareholders

Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

NXL

GlobeNewswire

a year ago

Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

NXL

GlobeNewswire

a year ago

Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device

Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device

NXL

News Direct

a year ago

Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

NXL

GlobeNewswire

a year ago

Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board

Nexalin Technology Full Year 2023 Earnings: US$0.63 loss per share (vs US$0.30 loss in FY 2022)

NXL

Simply Wall St.

a year ago

Nexalin Technology Full Year 2023 Earnings: US$0.63 loss per share (vs US$0.30 loss in FY 2022)

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

NXL

GlobeNewswire

a year ago

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology

NXL

GlobeNewswire

a year ago

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology

Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

NXL

GlobeNewswire

a year ago

Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

NXL

GlobeNewswire

a year ago

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

NXL

GlobeNewswire

a year ago

Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device

Hempacco to Exhibit at the 2024 Tobacco Plus Expo (TPE) in Las Vegas, Booth #25086

NXL

Newsfile

a year ago

Hempacco to Exhibit at the 2024 Tobacco Plus Expo (TPE) in Las Vegas, Booth #25086

Gulf Resources Announces the Completion of the Flood Prevention Project

NXL

GlobeNewswire

a year ago

Gulf Resources Announces the Completion of the Flood Prevention Project

NXL

Business Wire

a year ago

Innventure LLC and Learn CW Investment Corporation Announce Filing of Registration Statement on Form S-4 in Connection With Proposed Business Combination

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

NXL

GlobeNewswire

a year ago

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

NXL

Business Wire

a year ago

Learn CW Investment Corporation Extends Period to Consummate Initial Business Combination

NXL

GlobeNewswire

a year ago

A Record Revenue Year for Maris-Tech.

Nexalin Technology Unveils Next-Generation HALO™ Clarity

NXL

GlobeNewswire

a year ago

Nexalin Technology Unveils Next-Generation HALO™ Clarity

10 Supplements for Longevity and Antiaging: Expert Recommendations

NXL

Insider Monkey

a year ago

10 Supplements for Longevity and Antiaging: Expert Recommendations

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

NXL

GlobeNewswire

a year ago

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

NXL

GlobeNewswire

a year ago

Nexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression

NXL

Thomson Reuters StreetEvents

a year ago

Q4 2023 Good Times Restaurants Inc Earnings Call

NXL

Associated Press Finance

a year ago

Good Times Restaurants: Fiscal Q4 Earnings Snapshot

Good Times Restaurants Reports Results for the Fourth Quarter and Fiscal Year Ended September 26, 2023

NXL

Business Wire

a year ago

Good Times Restaurants Reports Results for the Fourth Quarter and Fiscal Year Ended September 26, 2023

Aadi Bioscience, Inc. (NASDAQ:AADI) is definitely on the radar of institutional investors who own 39% of the company

NXL

Simply Wall St.

a year ago

Aadi Bioscience, Inc. (NASDAQ:AADI) is definitely on the radar of institutional investors who own 39% of the company

HeartCore Implements New Function to Enhance its Market Leading CMS Platform

NXL

GlobeNewswire

a year ago

HeartCore Implements New Function to Enhance its Market Leading CMS Platform

Here's Why We're Watching BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation

NXL

Simply Wall St.

a year ago

Here's Why We're Watching BriaCell Therapeutics' (TSE:BCT) Cash Burn Situation

MoneyHero to Announce Third Quarter 2023 Financial Results

NXL

GlobeNewswire

a year ago

MoneyHero to Announce Third Quarter 2023 Financial Results

CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction

NXL

GlobeNewswire

a year ago

CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction

NXL

Business Wire

a year ago

Latest Nexalin Technology Inc. (NXL) News on May 9, 2025

Share on Social Networks: